Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 599

1.

Characteristics of air pollutants inside and outside a primary school classroom in Beijing and respiratory health impact on children.

Zhang L, Morisaki H, Wei Y, Li Z, Yang L, Zhou Q, Zhang X, Xing W, Hu M, Shima M, Toriba A, Hayakawa K, Tang N.

Environ Pollut. 2019 Aug 30;255(Pt 1):113147. doi: 10.1016/j.envpol.2019.113147. [Epub ahead of print]

PMID:
31522002
2.

A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.

Shima M, Nogami K, Nagami S, Yoshida S, Yoneyama K, Ishiguro A, Suzuki T, Taki M.

Haemophilia. 2019 Sep 12. doi: 10.1111/hae.13848. [Epub ahead of print]

PMID:
31515851
3.

[ALLERGY AND ENVIRONMENT, INCLUDING THE JAPAN ENVIRONMENT AND CHILDREN'S STUDY (JECS)].

Shima M.

Arerugi. 2019;68(7):840-845. doi: 10.15036/arerugi.68.840. Japanese. No abstract available.

PMID:
31406079
4.

The Characteristics of Polycyclic Aromatic Hydrocarbons in Different Emission Source Areas in Shenyang, China.

Yang L, Suzuki G, Zhang L, Zhou Q, Zhang X, Xing W, Shima M, Yoda Y, Nakatsubo R, Hiraki T, Sun B, Fu W, Qi H, Hayakawa K, Toriba A, Tang N.

Int J Environ Res Public Health. 2019 Aug 7;16(16). pii: E2817. doi: 10.3390/ijerph16162817.

5.

Questionnaire survey on maternal pertussis vaccination for pregnant women and mothers in Nara prefecture, Japan.

Kitano T, Onishi T, Takeyama M, Shima M.

Hum Vaccin Immunother. 2019 Sep 5:1-5. doi: 10.1080/21645515.2019.1651000. [Epub ahead of print]

PMID:
31368853
6.

A novel simultaneous clot-fibrinolysis waveform analysis for assessing fibrin formation and clot lysis in haemorrhagic disorders.

Nogami K, Matsumoto T, Sasai K, Ogiwara K, Arai N, Shima M.

Br J Haematol. 2019 Jul 23. doi: 10.1111/bjh.16111. [Epub ahead of print]

PMID:
31335970
7.

[Congenital hemophilia: a new treatment paradigm].

Shima M.

Rinsho Ketsueki. 2019;60(6):647-658. doi: 10.11406/rinketsu.60.647. Review. Japanese.

PMID:
31281158
8.

Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis.

Yada K, Nogami K, Ogiwara K, Shida Y, Furukawa S, Yaoi H, Takeyama M, Kasai R, Shima M.

Int J Hematol. 2019 Jun 28. doi: 10.1007/s12185-019-02698-8. [Epub ahead of print]

PMID:
31254165
9.

Short-Term Effects of Carbonaceous Components in PM2.5 on Pulmonary Function: A Panel Study of 37 Chinese Healthy Adults.

Huang S, Feng H, Zuo S, Liao J, He M, Shima M, Tamura K, Li Y, Ma L.

Int J Environ Res Public Health. 2019 Jun 26;16(13). pii: E2259. doi: 10.3390/ijerph16132259.

10.

Hemostatic function on hyper-fibrinolytic disseminated intravascular coagulation.

Ishihara T, Nogami K, Onishi T, Ogiwara K, Ochi S, Yamazaki M, Shima M.

Pediatr Int. 2019 Jun 22. doi: 10.1111/ped.13919. [Epub ahead of print]

PMID:
31228869
11.

The central role of thrombin in bleeding disorders.

Negrier C, Shima M, Hoffman M.

Blood Rev. 2019 May 22:100582. doi: 10.1016/j.blre.2019.05.006. [Epub ahead of print] Review.

12.

Evaluation of influenza vaccine-induced cell-mediated immunity: Comparison between methods using peripheral blood mononuclear cells and whole blood.

Otani N, Shima M, Ueda T, Ichiki K, Nakajima K, Takesue Y, Okuno T.

Microbiol Immunol. 2019 Jun;63(6):223-228. doi: 10.1111/1348-0421.12687. Epub 2019 Jun 17.

PMID:
31070266
13.

Involvement of the ADAMTS13-VWF axis in acute Kawasaki disease and effects of intravenous immunoglobulin.

Tsujii N, Nogami K, Matsumoto M, Yoshizawa H, Takase T, Tanaka I, Sakai T, Fukuda K, Hayakawa M, Sakai K, Isonishi A, Matsuura K, Fujimura Y, Shima M.

Thromb Res. 2019 Jul;179:1-10. doi: 10.1016/j.thromres.2019.04.026. Epub 2019 Apr 24.

PMID:
31055186
14.

Stronger association between particulate air pollution and pulmonary function among healthy students in fall than in spring.

Yoda Y, Takagi H, Wakamatsu J, Ito T, Nakatsubo R, Horie Y, Hiraki T, Shima M.

Sci Total Environ. 2019 Jul 20;675:483-489. doi: 10.1016/j.scitotenv.2019.04.268. Epub 2019 Apr 18.

PMID:
31030154
15.

Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS).

Mahlangu J, Oldenburg J, Callaghan MU, Shima M, Mancuso ME, Trask P, Recht M, Garcia C, Yang R, Lehle M, Macharia H, Asikanius E, Levy GG, Kruse-Jarres R, von Mackensen S.

Haemophilia. 2019 May;25(3):382-391. doi: 10.1111/hae.13731. Epub 2019 Apr 24.

PMID:
31016855
16.

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.

Pipe SW, Shima M, Lehle M, Shapiro A, Chebon S, Fukutake K, Key NS, Portron A, Schmitt C, Podolak-Dawidziak M, Selak Bienz N, Hermans C, Campinha-Bacote A, Kiialainen A, Peerlinck K, Levy GG, Jiménez-Yuste V.

Lancet Haematol. 2019 Jun;6(6):e295-e305. doi: 10.1016/S2352-3026(19)30054-7. Epub 2019 Apr 16.

PMID:
31003963
17.

Hemostatic assessment of combined anticoagulant therapy using warfarin and prothrombin complex concentrates in a case of severe protein C deficiency.

Ogiwara K, Nogami K, Mizumachi K, Nakagawa T, Noda N, Ohga S, Shima M.

Int J Hematol. 2019 Jun;109(6):650-656. doi: 10.1007/s12185-019-02645-7. Epub 2019 Apr 8.

PMID:
30963470
18.

Whole blood ristocetin-induced platelet impedance aggregometry does not reflect clinical severity in patients with type 1 von Willebrand disease.

Nakajima Y, Nogami K, Yada K, Ogiwara K, Furukawa S, Shimonishi N, Shima M.

Haemophilia. 2019 May;25(3):e174-e179. doi: 10.1111/hae.13725. Epub 2019 Mar 13.

PMID:
30866149
19.

Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).

Curry N, Albayrak C, Escobar M, Andre Holme P, Kearney S, Klamroth R, Misgav M, Négrier C, Wheeler A, Santagostino E, Shima M, Landorph A, Tønder SM, Lentz SR.

Haemophilia. 2019 May;25(3):373-381. doi: 10.1111/hae.13712. Epub 2019 Feb 28.

PMID:
30817066
20.

Pediatric phantom tumor caused by cardiac catheterization.

Tsujii N, Hayashi T, Yoshizawa H, Fukuba R, Yokoyama S, Shima M.

Pediatr Int. 2019 Feb;61(2):214. doi: 10.1111/ped.13750. No abstract available.

PMID:
30809879
21.

Potential role of activated factor VIII (FVIIIa) in FVIIa/tissue factor-dependent FXa generation in initiation phase of blood coagulation.

Furukawa S, Nogami K, Ogiwara K, Shima M.

Int J Hematol. 2019 Apr;109(4):390-401. doi: 10.1007/s12185-019-02611-3. Epub 2019 Feb 13.

PMID:
30756344
22.

Ventilator-associated events: prevalence and mortality in Japan.

Nakahashi S, Imai H, Imanaka H, Ohshimo S, Satou T, Shima M, Yanagisawa M, Yamashita C, Ogura T, Yamada T, Shime N.

J Thorac Dis. 2018 Dec;10(12):6942-6949. doi: 10.21037/jtd.2018.12.40.

23.

Association between chemical components of PM2.5 and children's primary care night-time visits due to asthma attacks: A case-crossover study.

Yamazaki S, Shima M, Yoda Y, Kurosaka F, Isokawa T, Shimizu S, Ogawa T, Kamiyoshi N, Terada K, Nishikawa J, Hanaoka K, Yamada T, Matsuura S, Hongo A, Yamamoto I.

Allergol Int. 2019 Jul;68(3):329-334. doi: 10.1016/j.alit.2019.01.001. Epub 2019 Feb 7.

24.

Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting.

Kruse-Jarres R, Oldenburg J, Santagostino E, Shima M, Kempton CL, Kessler CM, Lehle M, Chebon S, Selak Bienz N, Asikanius E, Mahlangu J.

Haemophilia. 2019 Mar;25(2):213-220. doi: 10.1111/hae.13655. Epub 2019 Feb 6.

PMID:
30724422
25.

Miscorrelation of Functional Outcome and Sociooccupational Status of Childhood, Adolescent, and Young Adult Generation With Bone and Soft Tissue Sarcoma Patients.

Fujii H, Honoki K, Ishihara T, Shinomiya T, Tsukamoto S, Kido A, Kondoh Y, Kishi S, Shima M, Tanaka Y.

J Pediatr Hematol Oncol. 2019 Mar;41(2):112-117. doi: 10.1097/MPH.0000000000001410.

PMID:
30688829
26.

Dioxins levels in human blood after implementation of measures against dioxin exposure in Japan.

Muzembo BA, Iwai-Shimada M, Isobe T, Arisawa K, Shima M, Fukushima T, Nakayama SF.

Environ Health Prev Med. 2019 Jan 10;24(1):6. doi: 10.1186/s12199-018-0755-7.

27.

Population-based cohort study on health effects of asbestos exposure in Japan.

Zha L, Kitamura Y, Kitamura T, Liu R, Shima M, Kurumatani N, Nakaya T, Goji J, Sobue T.

Cancer Sci. 2019 Mar;110(3):1076-1084. doi: 10.1111/cas.13930. Epub 2019 Feb 6.

28.

Inhibitor development, safety and efficacy of Advate® among previously treated patients with hemophilia A in a postmarketing surveillance in Japan.

Fukutake K, Taki M, Matsushita T, Nogami K, Shima M, Yoshioka A, Takamatsu J, Uchikawa H, Takagi H, Arai M, Engl W, Shirahata A.

Int J Hematol. 2019 Mar;109(3):336-345. doi: 10.1007/s12185-018-02574-x. Epub 2019 Jan 2.

PMID:
30604312
29.

Dynamic evaluation of hemostasis in the acute phase of Kawasaki disease using comprehensive coagulation functional assays.

Yoshizawa H, Nogami K, Matsumoto T, Tsujii N, Sakai T, Takase T, Tanaka I, Shima M.

Thromb Res. 2019 Feb;174:76-83. doi: 10.1016/j.thromres.2018.12.016. Epub 2018 Dec 13.

PMID:
30579149
30.

Correction to: Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan.

Taki M, Fukutake K, Matsushita T, Nogami K, Shima M, Yoshioka A, Takamatsu J, Arai M, Takagi H, Uchikawa H, Engl W, Shirahata A.

Int J Hematol. 2019 Feb;109(2):241. doi: 10.1007/s12185-018-02564-z.

PMID:
30560315
31.

New therapies using nonfactor products for patients with hemophilia and inhibitors.

Nogami K, Shima M.

Blood. 2019 Jan 31;133(5):399-406. doi: 10.1182/blood-2018-07-820712. Epub 2018 Dec 17. Review.

PMID:
30559263
32.

A case of moderate haemophilia A with inhibitor, carrying the p.R1800H mutation, complicated with juvenile idiopathic arthritis.

Kondo Y, Shida Y, Ishikawa T, Yada K, Takeyama M, Shima M, Nogami K.

Haemophilia. 2019 Jan;25(1):e51-e54. doi: 10.1111/hae.13648. Epub 2018 Dec 3. No abstract available.

PMID:
30507053
33.

Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro.

Minami H, Nogami K, Yada K, Ogiwara K, Furukawa S, Soeda T, Kitazawa T, Shima M.

J Thromb Haemost. 2019 Jan;17(1):126-137. doi: 10.1111/jth.14334. Epub 2018 Dec 10.

PMID:
30444568
34.

The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.

Oldenburg J, Mahlangu JN, Bujan W, Trask P, Callaghan MU, Young G, Asikanius E, Peyvandi F, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Xu J, Windyga J, Shima M, von Mackensen S.

Haemophilia. 2019 Jan;25(1):33-44. doi: 10.1111/hae.13618. Epub 2018 Nov 14.

35.

Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.

Kitazawa T, Shima M.

Int J Hematol. 2018 Oct 22. doi: 10.1007/s12185-018-2545-9. [Epub ahead of print] Review.

PMID:
30350119
36.

Factors for inhibition of early discharge from the psychiatric emergency ward for elderly patients.

Adachi S, Komiya T, Nomura K, Shima M.

Environ Health Prev Med. 2018 Oct 10;23(1):48. doi: 10.1186/s12199-018-0738-8.

37.

Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study.

Mahlangu J, Oldenburg J, Callaghan MU, Shima M, Santagostino E, Moore M, Recht M, Garcia C, Yang R, Lehle M, Macharia H, Asikanius E, Levy GG, Kruse-Jarres R.

Haemophilia. 2018 Nov;24(6):921-929. doi: 10.1111/hae.13612. Epub 2018 Oct 8.

PMID:
30295389
38.

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.

Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jiménez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R.

N Engl J Med. 2018 Aug 30;379(9):811-822. doi: 10.1056/NEJMoa1803550.

39.

Association of airborne particles, protein, and endotoxin with emergency department visits for asthma in Kyoto, Japan.

Khan MS, Coulibaly S, Matsumoto T, Yano Y, Miura M, Nagasaka Y, Shima M, Yamagishi N, Wakabayashi K, Watanabe T.

Environ Health Prev Med. 2018 Aug 28;23(1):41. doi: 10.1186/s12199-018-0731-2.

40.

Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.

Yada K, Nogami K, Shinozawa K, Kitazawa T, Hattori K, Amano K, Fukutake K, Shima M.

Br J Haematol. 2018 Oct;183(2):257-266. doi: 10.1111/bjh.15525. Epub 2018 Aug 20.

PMID:
30125997
41.

Prevention of surgical site infection via antibiotic administration according to guidelines after gynecological surgery.

Toba M, Moriwaki M, Oshima N, Aiso Y, Shima M, Nukui Y, Obayashi S, Fushimi K.

J Obstet Gynaecol Res. 2018 Sep;44(9):1800-1807. doi: 10.1111/jog.13714. Epub 2018 Jul 26.

PMID:
30051538
42.

Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan.

Taki M, Fukutake K, Matsushita T, Nogami K, Shima M, Yoshioka A, Takamatsu J, Arai M, Takagi H, Uchikawa H, Engl W, Shirahata A.

Int J Hematol. 2019 Jan;109(1):70-78. doi: 10.1007/s12185-018-2499-y. Epub 2018 Jul 24. Erratum in: Int J Hematol. 2018 Dec 17;:.

PMID:
30043332
43.

Advantages, disadvantages and optimization of one-stage and chromogenic factor activity assays in haemophilia A and B.

Adcock DM, Strandberg K, Shima M, Marlar RA.

Int J Lab Hematol. 2018 Dec;40(6):621-629. doi: 10.1111/ijlh.12877. Epub 2018 Jul 6. Review.

PMID:
29979821
44.

The Japanese Immune Tolerance Induction (J-ITI) study in haemophilia patients with inhibitor: Outcomes and successful predictors of ITI treatment.

Nogami K, Taki M, Matsushita T, Ohga S, Oka T, Horikoshi Y, Amano K, Shima M.

Haemophilia. 2018 Sep;24(5):e328-e337. doi: 10.1111/hae.13531. Epub 2018 Jun 14.

PMID:
29902361
45.

Principles of haemophilia care: The asia pacific perspective. Response.

Dunkley S, Lam JCM, John MJ, Wong RSM, Tran H, Yang R, Nair SC, Shima M, Street A, Srivastava A.

Haemophilia. 2018 Jul;24(4):e243-e244. doi: 10.1111/hae.13522. Epub 2018 Jun 14. No abstract available.

PMID:
29901827
46.

Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.

Nogami K, Soeda T, Matsumoto T, Kawabe Y, Kitazawa T, Shima M.

J Thromb Haemost. 2018 Jul;16(7):1383-1390. doi: 10.1111/jth.14135. Epub 2018 May 27.

PMID:
29734520
47.

Spatiotemporal land use random forest model for estimating metropolitan NO2 exposure in Japan.

Araki S, Shima M, Yamamoto K.

Sci Total Environ. 2018 Sep 1;634:1269-1277. doi: 10.1016/j.scitotenv.2018.03.324. Epub 2018 Apr 18.

PMID:
29710628
48.

The factor VIII heavy chain improves emicizumab-tenase assembly to enhance the factor VIII-mimicking cofactor activity.

Minami H, Nogami K, Soeda T, Kitazawa T, Hattori K, Shima M.

Thromb Res. 2018 Jun;166:77-79. doi: 10.1016/j.thromres.2018.04.016. Epub 2018 Apr 17. No abstract available.

PMID:
29684725
49.

Relationship between the frequency of influenza vaccination and cell-mediated immunity.

Otani N, Shima M, Ueda T, Ichiki K, Nakajima K, Takesue Y, Honjo K, Yoshida N, Kawata S, Okuno T.

J Immunol Methods. 2018 Jul;458:58-62. doi: 10.1016/j.jim.2018.04.008. Epub 2018 Apr 21.

PMID:
29684427
50.

Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.

Nogami K, Matsumoto T, Tabuchi Y, Soeda T, Arai N, Kitazawa T, Shima M.

J Thromb Haemost. 2018 Jun;16(6):1078-1088. doi: 10.1111/jth.14022. Epub 2018 May 13.

PMID:
29645406

Supplemental Content

Support Center